Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Coherus Oncology (CHRS) over the last 8 years, with Q3 2025 value amounting to $88.3 million.

  • Coherus Oncology's Short-term Investments changed N/A to $88.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.3 million, marking a year-over-year change of. This contributed to the annual value of $14.9 million for FY2023, which is 8840.51% down from last year.
  • Latest data reveals that Coherus Oncology reported Short-term Investments of $88.3 million as of Q3 2025.
  • In the past 5 years, Coherus Oncology's Short-term Investments registered a high of $140.0 million during Q1 2021, and its lowest value of $14.9 million during Q4 2023.
  • Its 4-year average for Short-term Investments is $85.9 million, with a median of $98.2 million in 2021.
  • Per our database at Business Quant, Coherus Oncology's Short-term Investments tumbled by 4623.0% in 2021 and then plummeted by 8840.51% in 2023.
  • Coherus Oncology's Short-term Investments (Quarter) stood at $108.2 million in 2021, then increased by 18.46% to $128.1 million in 2022, then plummeted by 88.41% to $14.9 million in 2023, then soared by 494.41% to $88.3 million in 2025.
  • Its Short-term Investments stands at $88.3 million for Q3 2025, versus $20.7 million for Q2 2025 and $14.9 million for Q4 2023.